Nanalysis Settles Interest Payment on Promissory Notes and Provides Corporate Update

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/

CALGARY, AB, Nov. 3, 2026 /CNW/ -- Nanalysis Scientific Corp. (the "Company" or "Nanalysis") (TSXV: NSCI, FRA: 1N1) is pleased to announce that it has satisfied the first annual interest payment of $240,000 owing on its unsecured promissory notes (the "Notes") through the issuance of an aggregate of 2,000,000 common shares of the Company (the "Interest Shares") at a deemed price of $0.12 per Interest Share (the "Interest Payment").

The Notes were issued on June 13, 2025 to arm's length third-party investors (the "Lenders") in the aggregate principal amount of $2,000,000, as previously announced by the Company in its news release dated June 13, 2025. The Notes mature on June 13, 2027, and bear simple interest at a rate of 12% per annum, payable annually. At the Company's option and subject to TSX Venture Exchange (the "TSXV") approval, the interest may be paid in cash or common shares of the Company. The Interest Shares were issued to the Lenders pro rata in accordance with their respective holdings of Notes.

The issuance of the Interest Shares remains subject to the final acceptance of the TSXV. The Interest Shares are subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities legislation and the policies of the TSXV.

Corporate Update

The Company also announces that Philip Birkby, who has served as Interim Chief Financial Officer of the Company since October 5, 2026, has stepped down from the role effective October 31, 2026. Mr. Birkby will remain with Nanalysis in a consulting capacity.

In his consulting role, Mr. Birkby will continue to support the Company on financial reporting, treasury and other finance matters, providing continuity while the Company resumes its search for a permanent Chief Financial Officer. The Company will provide an update on the appointment of a permanent Chief Financial Officer in due course.

"On behalf of the Board and the entire Nanalysis team, we thank Phil for his contributions as Interim Chief Financial Officer and are pleased that the Company will continue to benefit from his experience going forward," said Sean Krakiwsky, Chief Executive Officer of Nanalysis.

About Nanalysis Scientific Corp. (TSXV: NSCI, FRA: 1N1)

Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers used worldwide in pharma, biotech, energy, food, materials, and security industries, as well as in academic and government labs. The Company also operates a growing services division that maintains both its own products and third-party imaging equipment, anchored by a $160 million long-term contract with the Canadian Air Transport Security Authority (CATSA) to maintain security scanners at more than 80 Canadian airports.

Notice regarding Forward Looking Information and Legal Disclaimer

This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking information is frequently characterized by words such as "anticipate", "plan", "continue", "expect", "project", "intend", "believe", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. In particular, this news release contains forward-looking information in relation to the Interest Payment, the receipt of TSXV final acceptance of the issuance of the Interest Shares, the transition of the Interim Chief Financial Officer to a consulting role and the Company's search for a permanent Chief Financial Officer. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information in this news release, including that the TSXV will accept the issuance of the Interest Shares on the terms described herein. Forward-looking information is based on the opinions and estimates of management as at the date it is made and is subject to a variety of risks, uncertainties and other factors that could cause actual events or results to differ materially from those projected, including the risk that TSXV final acceptance is not obtained. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws, unless an exemption from such registration is available.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Nanalysis Scientific Corp.

For Further Information: Nanalysis Scientific Corp., Sean Krakiwsky, CEO, E-mail: [email protected]; Jake Bouma - JT Pacific Capital Partners Corp., Email: [email protected]